Allowing Hundreds of Hospitals Access to an Effective Protein Detection Test
Cambridge, UK - 24.06.2013: Scientific Digital Imaging [SDI’s] Synoptics Health Division, a manufacturer of innovative digital imaging systems for healthcare applications is pleased to announce the appointment of distributors throughout the Asia-Pacific region. These new distributors will ensure sterile services department (SSD) personnel in hospitals here can easily access Synoptics Health’s unique ProReveal system, a highly sensitive in-situ fluorescence-based test to detect nanogram levels of protein contamination on surgical instruments.
In just six months, Synoptics Health has appointed six new distributors including Ruhof China, (www.ruhofchina.com) covering China and Taiwan, GSI Creos Corporation in Japan, In Vitro Technologies (www.invitro.com/au) in Australia, PharmaTech Inc in South Korea (www.pharmatech.co.kr), V-Bio Science (www.v-bioscience.com) in Malaysia and Lab Focus Co Ltd (www.labfocus.co.th) in Thailand. Under the terms of the agreements, distributors will market and support Synoptics Health’s ProReveal portfolio of products, which includes the ProReveal viewer and fluorescence testing kits in their assigned regions.
Synoptics Health distributors are organising ProReveal seminars for SSD personnel in over 50 hospitals across the Asia-Pacific region during 2013. During these seminars, Synoptics Health experts will introduce the ProReveal technology and present trial data, to show that ProReveal’s protein detection is around 100 times more sensitive than tests currently being used in SSDs.
Paul Ellwood, SDI Synoptics Health’s CEO explained: “The need to improve the decontamination processes used in hospitals world-wide is currently a major issue since dirty instruments can result in costly hospital closures and more importantly, can lead to patients being infected. The ProReveal technology launched in 2012 is the only commercial test that will meet new upcoming Department of Health guidelines on minimum safe protein contamination levels and using this test in hospitals in the Asia-Pacific region will ensure that surgical instruments are being properly checked for contamination from proteins such as prions that cause vCJD.”
Mike Creedon SDI’s Chief Executive Officer, added: “Asia-Pacific is a rapidly developing region for healthcare products and we’re delighted that companies specialising in this sector have recognised ProReveal’s benefits. This has allowed us in just six months to build an extensive network of partners and we’re also looking to add further distributors here. Since SDD personnel in this region are keen to enhance the quality of their instrument decontamination processes, the potential market for ProReveal is huge and if widely adopted could significantly improve infection control for thousands of patients undertaking surgical operations in hospitals throughout the Asia-Pacific region.”
About Synoptics Health
Synoptics Health, based in Cambridge, UK is a division of the Synoptics Group of the AIM listed Scientific Digital Imaging (SDI) Company based in Cambridge, UK. Synoptics is a world-leader in the development and manufacture of innovative digital imaging systems for a range of life science applications. The Group has three other divisions, Syngene, Syncroscopy and Synbiosis of which Syngene is the largest.
Syngene produces advanced systems for molecular biologists to analyse and document fluorescent DNA on gels and has systems in all the major pharmas and academic institutes world-wide. Synoptics’ other divisions Syncroscopy and Synbiosis specialise in digital imaging solutions for microscopy and microbial applications respectively. SDI’s Synoptics Group was founded in 1986 and currently employs 45 people, 20 of whom are based at Synoptics Inc. in the USA.
For Further Information Contact:
Jayne Arthur, Synoptics Health, Beacon House
Nuffield Road, Cambridge, CB4 1TF, UK.
Tel: +44(0) 1223-727114 Fax +44 (0) 1223-727101
Web site: www.synopticshealth.com